期刊文献+

成纤维细胞生长因子对多巴胺神经元的保护作用

Neuroprotective Effects of Fibroblast Growth Factor on Dopaminergic Cells in Vitro
下载PDF
导出
摘要 目的:探讨成纤维细胞生长因子(FGF)对多巴胺能神经元的保护作用及其机制。方法:体外培养大鼠肾上腺嗜铬细胞瘤细胞(PC12细胞),用6-羟基多巴胺(6-OHDA)和FGF分别或共处理PC12细胞,MTT法观察6-OHDA和FGF对PC12细胞活力的影响,流式细胞术观察PC12细胞凋亡率变化,TBA法测定PC12细胞丙二醛(MDA)含量变化。结果:6-OHDA处理后PC12细胞出现浓度依赖性活力下降,FGF能够减轻PC12细胞活力下降程度,降低细胞凋亡率,同时降低PC12细胞内MDA水平。结论:FGF对多巴胺能神经元具有保护作用,其机制与降低细胞内氧化应激水平有关。 Objective:To investigate the neuroprotective effect of Fibroblast Growth Factor(FGF) on dopaminergic cells in vitro,and lay the basis for the neuroprotective treatment of Parkinson disease.Method:PC12 cell were treated with 6-OHDA to establish the cellular model of dopaminergic neuronal damage.MTT assay was used to detect the cell viability of PC12 cells; flow cytometry was used to detect the apoptosis of PC12 cells.And the level of oxidative stress was detected by spectrophotometer.Results:The cell viability of PC12 cells decreased in a concentration dependent manner after 6-OHDA treatment.Exposure to FGF increased the cell viability of PC12 cells significantly,while the apoptotic rate decreased in the FGF treated group.The level of oxidative stress was also significantly decreased by FGF.Conclusion:FGF protects PC12 cells from the neurotoxic effect of 6-OHDA.This neuroprotective effect can be at least partly attributed to the inhibition of oxidative stress.
作者 徐芳 魏桂荣
出处 《微循环学杂志》 2010年第4期16-18,F0004,共4页 Chinese Journal of Microcirculation
基金 国家自然科学基金资助项目(30570627)
关键词 多巴胺神经元 成纤维细胞生长因子 保护作用 神经元变性 神经保护治疗 神经营养因子 替代治疗 黑质致密部 Adrenal pheochromocytoma cell Fibroblast growth factor Oxidative stress Parkinson disease
  • 相关文献

参考文献7

  • 1Vargas MR,Pehar M,Cassina P,et al.Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes:consequences for motor neuron survival.J Biol Chem,2005,280(27):25 571-25 579.
  • 2Rodriguez-Blanco J,Martin V,Herrera F,et al.Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine.J Neurochem,2008,107(1):127-140.
  • 3Schapira AH.Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.Neurology,2009,72(7 Suppl):S44-50.
  • 4Grothe C,Timmer M.The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system.Brain Res Rev,2007,54(1):80-91.
  • 5Gallagher DA,Schapira AH.Etiopathogenesis and treatment of Parkinson's disease.Curr Top Med Chem,2009,9(10):860-868.
  • 6Levy OA,Malagelada C,Greene LA.Cell death pathways in Parkinson's disease:proximal triggers,distal effectors,and final steps.Apoptosis,2009,14(4):478-500.
  • 7Bloomer RJ,Schilling BK,Karlage RE,et al.Effect of resistance training on blood oxidative stress in Parkinson disease.Med Sci Sports Exerc,2008,40(8):1 385-1 389.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部